Clinical Trial

Effect of Rapamycin in Ovarian Aging

Study acronym: Rapamycin
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women. Animal studies have shown the potential of rapamycin in slowing or reversing some age-associated pathways.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-04-17; most recent amendment 2025-12-23.
Status change: Recruiting → Active, Not Recruiting 2025-01-03
Status change: Not Yet Recruiting → Recruiting 2023-05-12
Trial Details
NCT Number NCT05836025
Lead Sponsor Columbia University
Conditions Perimenopausal
Enrollment 50 participants
Start Date 2023-06-01
Primary Completion 2025-10-21 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-26